Update on Novel B-Cell Receptor Signaling Inhi... - CLL Support

CLL Support

23,337 members40,044 posts

Update on Novel B-Cell Receptor Signaling Inhibitors from NCCN 8th Annual Congress on Hematologic Malignancies

AussieNeil profile image
AussieNeilPartnerAdministrator
1 Reply

The article below from OncLive, provides a high level overview of trials experience of the new drugs Ibrutinib, Idelalisib and IPI-145 by Jeffrey Jones, MD, from The Ohio State University to the NCCN 8th Annual Congress on Hematologic Malignancies. Brief mention is also made of the benefits observed when using Ibrutinib with Ofatumumab (Arzerra) and rituximab.

Drugs targeting B-cell receptor (BCR) signaling pathways are improving outcomes for patients with B-cell lymphomas, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and mantle cell lymphoma (MCL). These novel agents include PI3-Kinase (PI3K) inhibitors (eg, idelalisib) and Bruton’s tyrosine kinase (BTK) inhibitors (eg, ibrutinib), and are considered a breakthrough for CLL and other B-cell lymphomas.

At the recent NCCN 8th Annual Congress on Hematologic Malignancies, Jeffrey Jones, MD, from The Ohio State University Comprehensive Cancer Center and James Cancer Hospital and Solove Research Institute, updated listeners on these two new targeted drug classes:

onclive.com/publications/ob...

Neil

(This Musk Lorikeet proved challenging to photograph, as it was very actively foraging for nectar and pollen from the bottlebrush shrub.)

Written by
AussieNeil profile image
AussieNeil
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply
MartyR profile image
MartyR

Neil, it seems to be the conference time of the year - yet another positive article about these inhibitors

Although is it compulsory to swallow a dictionary before standing on stage!

Definition of concomitant in English --- naturally accompanying or associated:

she loved travel, with all its concomitant worries

Great photo - most UK birds are black, grey or brown - I suppose our birds needed to hide from hunters whereas your birds can see and hear a boomerang coming!!!!

Marty

Not what you're looking for?

You may also like...

YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success

I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
AussieNeil profile image
Partner

A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor

How does zanubrutinib differ from ibrutinib in pharmacokinetics and target occupancy? Zanubrutinib...
Jm954 profile image
Administrator

Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD

Advances in Targeted Therapy for R/R CLL (These OncLive presentations are intended for medical...
lankisterguy profile image
Volunteer

Ibrutinib Slow but steady foreward movement.

Slowly things move forwards… New Marketing Authorisation Application Submitted to EMA for...
Kwenda profile image

Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects

August 16, 2020 Fewer off-target effects mean second-generation BTK inhibitors offer less...
Jm954 profile image
Administrator

Moderation team

See all
Newdawn profile image
NewdawnAdministrator
AussieNeil profile image
AussieNeilAdministrator
CLLerinOz profile image
CLLerinOzAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.